JB Chemicals & Pharmaceuticals Ltd. (IN:JBCHEPHARM)
:JBCHEPHARM
Want to see IN:JBCHEPHARM full AI Analyst Report?
JBCHEPHARM Stock Chart & Stats
₹1847.80
-₹0.05(>-0.01%)
At close: 4:00 PM EST
₹1847.80
-₹0.05(>-0.01%)
Day’s Range― - ―
52-Week Range₹1,603.05 - ₹2,284.95
Previous CloseN/A
Volume153.25K
Average Volume (3M)2.67K
Market Cap
₹361.55B
Enterprise Value₹346.57B
Total Cash (Recent Filing)₹9.01B
Total Debt (Recent Filing)₹409.10M
Price to Earnings (P/E)50.7
Beta0.53
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.86%
Share Statistics
EPS (TTM)46.08
Shares Outstanding160,558,700
10 Day Avg. Volume4,569
30 Day Avg. Volume2,671
Financial Highlights & Ratios
PEG Ratio7.16
Price to Book (P/B)7.80
Price to Sales (P/S)7.82
P/FCF Ratio51.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)61.74
Revenue Forecast (FY)₹47.81B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a strengthening equity base provide durable financial flexibility. Near-negligible debt reduces interest risk, supports investment or acquisitions, and helps absorb industry cyclicality, improving long-term resilience and strategic optionality.
Multi-year Revenue ExpansionSustained top-line growth over multiple years signals scalable product lines and market traction in domestic and export channels. This scale supports better fixed-cost absorption and strengthens the platform for continued R&D, market penetration, and margin recovery over time.
Recent Strong Cash GenerationImproved operating and free cash flow enhances the company's ability to self-fund capex, R&D, dividends, and buybacks. Reliable cash conversion in recent years reduces reliance on external financing and underpins long-term strategic investments and capital allocation.
Bears Say
Slowing Revenue GrowthA material deceleration to low-single-digit revenue growth weakens the growth runway and limits operating-leverage benefits. If persistent, slower top-line expansion will constrain earnings growth and the ability to scale margins without new product launches or geographic expansion.
Margin VolatilitySignificant year-to-year margin swings reduce earnings predictability and complicate long-term planning. Exposure to mix shifts, pricing pressure, and input-cost variability can compress cash flow and hinder consistent reinvestment or dividend policies.
Historical FCF VolatilityEpisodes of materially negative free cash flow highlight risks from working-capital swings or high capex cycles. Recurrence could strain liquidity and force external financing, limiting strategic choices despite the recent rebound in cash generation.
JB Chemicals & Pharmaceuticals Ltd. News
JBCHEPHARM FAQ
What was JB Chemicals & Pharmaceuticals Ltd.’s price range in the past 12 months?
JB Chemicals & Pharmaceuticals Ltd. lowest stock price was ₹1603.05 and its highest was ₹2284.95 in the past 12 months.
What is JB Chemicals & Pharmaceuticals Ltd.’s market cap?
JB Chemicals & Pharmaceuticals Ltd.’s market cap is ₹361.55B.
When is JB Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date?
JB Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 55 days.
How were JB Chemicals & Pharmaceuticals Ltd.’s earnings last quarter?
JB Chemicals & Pharmaceuticals Ltd. released its earnings results on May 11, 2026. The company reported ₹8.25 earnings per share for the quarter, missing the consensus estimate of ₹9.9 by -₹1.65.
Is JB Chemicals & Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts JB Chemicals & Pharmaceuticals Ltd.’s price is currently Overvalued.
Does JB Chemicals & Pharmaceuticals Ltd. pay dividends?
JB Chemicals & Pharmaceuticals Ltd. pays a Semiannually dividend of ₹9.3 which represents an annual dividend yield of 0.86%. See more information on JB Chemicals & Pharmaceuticals Ltd. dividends here
What is JB Chemicals & Pharmaceuticals Ltd.’s EPS estimate?
JB Chemicals & Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JB Chemicals & Pharmaceuticals Ltd. have?
JB Chemicals & Pharmaceuticals Ltd. has 160,558,700 shares outstanding.
What happened to JB Chemicals & Pharmaceuticals Ltd.’s price movement after its last earnings report?
JB Chemicals & Pharmaceuticals Ltd. reported an EPS of ₹8.25 in its last earnings report, missing expectations of ₹9.9. Following the earnings report the stock price went up 2.6%.
Which hedge fund is a major shareholder of JB Chemicals & Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:JBCHEPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JB Chemicals & Pharmaceuticals Ltd.
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Technical Analysis
Ajanta Pharma Limited
―
Emcure Pharmaceuticals Limited
―
Eris Lifesciences Ltd
―
IPCA Laboratories Limited
―
Wockhardt Limited
―